An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer (vol 27, pg 1058, 2022)
The oncologist（2023）
摘要
This ITC suggests a favorable benefit:risk profile for dostarlimab in patients with dMMR/MSI-H advanced/recurrent EC.
更多查看译文
关键词
DNA mismatch repair,doxorubicin,endometrial neoplasms,immune checkpoint inhibitors,microsatellite instability,uterine neoplasms
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要